Selecting an Electronic Data Capture (EDC) system for a single trial is one kind of decision. Selecting an EDC platform to use across every trial your company will run over the next several years is a fundamentally different one. The trial-level choice turns on a single study's requirements and typically defaults to whatever the CRO offers. The company-level choice commits you to a platform, a provider, a set of processes, and a service ecosystem that will shape every trial in your programme — and get considerably harder to change once you have trials in flight.
This guide sets out a macro criteria-based approach to company-level EDC selection. Rather than scoring candidate systems against a long list of trial-level functional requirements, the approach identifies the handful of factors that genuinely matter at company level and uses them as a consistent framework to shortlist candidates and verify the final decision. For a broader view of EDC system fundamentals, see our pillar article.
What Is Company-Level EDC Selection?
Company-level EDC selection is the process of choosing an EDC system — together with a supporting service model — to use as your default platform across your clinical development programme. Ownership in this context means you control the licence contract and system configuration, you own the standards libraries and any developed components, and you can have different CROs or vendors work within your system across different trials.
This differs from trial-by-trial selection in three important ways. First, the decision is strategic rather than operational: it is about your development programme, not about one protocol. Second, its benefits compound over time — a standards library, trained internal staff, and aligned CRO relationships become more valuable with every additional trial run on the platform. Third, it is hard to reverse once implemented: data in flight, contracts in place, and organisational investment all create real switching friction.
Why Company-Level EDC Selection Matters
A well-matched company EDC delivers benefits that a trial-by-trial approach cannot: cross-trial consistency in CRF design and edit checks, re-use of validated libraries to shorten study build timelines, independence from any single CRO, and significant cost savings from a direct enterprise contract with the system provider (typically 10–30% compared with trial-by-trial CRO pass-through pricing). These benefits generally begin to outweigh the burden of ownership around the 2–3 parallel trial mark and accelerate from there.
The risks of getting the decision wrong are equally strategic. A platform that works for your current Phase I trials but cannot flex to support the complex Phase III you will run in two years forces a mid-programme change at the worst possible time. A provider that fails financially leaves you managing an unplanned migration. An over-sized system that your internal team does not actually use becomes a sunk cost. And a choice made on the basis of what a larger company uses — without the infrastructure, trial volume, and sourcing model that make it work for them — delivers the downsides of ownership without the benefits.
Is Now the Right Time to Own an EDC System?
Before selecting any specific system, confirm that company-level ownership is the right call for your current stage. The benefits are real but conditional.
Consider ownership when:
- You have 2–3 or more parallel trials, or a pipeline that will reach that level soon
- Your trials share therapeutic area, protocol design, or data structure elements that benefit from a shared standards library
- You want the flexibility to work with different CROs on a consistent platform
- You have the internal capability — or can source it — to manage validation, standards, and oversight
- You work in therapeutic areas with complex or adaptive trial designs where cross-trial consistency matters from trial one
Delay ownership when:
- You are running one small early-phase trial with no defined pipeline beyond it
- Your strategy is full-service CRO outsourcing with no plan for cross-trial standardisation
- Internal capability or capacity is not yet in place to manage ownership responsibilities
- Your development programme direction is still genuinely uncertain
If the answer is "not yet," continue using CRO systems on a trial-by-trial basis — our guide to trial-level EDC selection covers that process in detail — and revisit the question as your pipeline develops. If the answer is "yes," proceed with a structured selection.
The Macro Criteria Framework for Company-Level Selection
Gone are the days of scoring five systems against 400 technical requirements. That approach fails at company level for the same reason it fails at trial level: it tries to compare incompatible factors — cost, functionality, service quality, compliance — in a single numerical score, and it obscures the dimensions that actually determine whether a platform will work for your organisation.
The macro criteria approach instead identifies 2–4 critical factors across four dimensions, uses them to shortlist candidate categories, and applies them as a consistent evaluation framework throughout. At company level, each dimension takes on a different emphasis than it would at trial level.
1. Functional Requirements (Across Your Pipeline)
At trial level, functional requirements are defined by one protocol. At company level, they must span your plausible pipeline — present and future. The key consideration here is the underlying EDC architecture and how it will flex to support what you will be running in three to five years, not just today. Consider:
- Range of trial types to support — Phase I dose-escalation through Phase III confirmatory trials have different demands. Select for the range, not just the current project.
- Therapeutic area complexity — oncology, rare disease, and CNS trials place different demands on CRF design, edit checks, and data review workflows.
- Standards library and re-use capabilities — the value of ownership comes largely from cross-trial re-use. How well does the system support library management?
- Integration with your wider architecture — does the system integrate cleanly with the CTMS, safety system, eTMF, ePRO, and analysis environments you use or plan to use?
- CDISC alignment — CDASH-aligned CRF design and SDTM mapping capability, now and as standards evolve.
The question is not "can it run this trial?" but "can it run the range of trials we will need over the next several years?"
2. Service Availability (At Your Scale)
At trial level, service availability means "can we get this one study built?" At company level, it means "can we get every trial we will run built, on time, with the quality we need, across the geographies and therapeutic areas in our programme?"
- Capacity across concurrent trials — can the provider ecosystem support all your parallel trials without resource conflicts?
- Global footprint — do qualified providers operate in the regions where your sites will run?
- Therapeutic area expertise depth — is there experienced study-build capacity in your therapeutic areas?
- Sourcing model fit — can you operate the sourcing model you want (FSP, multi-CRO, in-house build) on this platform?
- Provider choice — are there multiple qualified service providers for the system, or are you tied to one?
Service availability scales with market footprint. The largest systems have the widest ecosystem of CROs, study builders, and independent consultants; smaller systems may offer excellent software but narrow service options, which is a meaningful constraint if you depend on external expertise.
3. Company and System Match
A company-level EDC relationship is multi-year. How well your organisation matches the provider matters considerably more at company level than at trial level.
- Financial stability and ownership — what happens to your platform if the provider is acquired or fails? Is the provider positioned for the duration of your development programme?
- Product roadmap — is the system actively invested in? Does the development direction align with where your trials are going?
- Cultural and policy fit — do provider working practices, quality systems, and governance align with yours?
- Market footprint — how familiar is the system to CRAs and sites in your key geographies and therapeutic areas? Site users and CRAs represent the majority of system usage.
- Scalability with your growth — can the provider scale with you, or will you outgrow them?
4. Cost and Conditions
At trial level, cost comparison is straightforward. At company level, it must capture scaling economics, switching costs, and contractual flexibility over time.
- Enterprise contract economics — company-level contracts typically deliver 10–30% savings over trial-by-trial CRO pass-through pricing, with the break-even point sitting around 2–3 trials.
- Total cost across trials — implementation and standards library costs amortise across trials; service costs scale with volume.
- Contractual flexibility — change control provisions, volume adjustments, and service model flexibility.
- Data portability — clear exit terms for extracting data, metadata, and libraries if you later change platforms. This protects your optionality.
- Pricing model fit — per-subject, per-trial, per-user, and hybrid models have different implications at different trial volumes.
The Company-Level Selection Process: Step by Step
Step 1. Define your company strategy and activity architecture. Before any vendor conversation, document your pipeline trajectory, your sourcing model (in-house build, FSP, full outsourcing, or hybrid), and the split of activities between internal and external resources. This activity architecture determines which systems are relevant and what the service model needs to look like.
Step 2. Confirm ownership is the right call. Apply the own-or-source criteria to your current stage and pipeline. If ownership does not yet make sense, stop here and continue trial by trial — you can revisit the decision as your pipeline develops. If it does, proceed.
Step 3. Identify your macro criteria profile. Across the four dimensions — Functional Requirements, Service Availability, Company and System Match, and Cost and Conditions — select the 2–4 factors that matter most for your organisation. Define what "good enough" looks like in each. This profile becomes both your shortlisting filter and your final evaluation framework.
Step 4. Map macro criteria to system categories. The EDC market divides broadly into five categories: Category 1 large full-suite systems (Medidata, Oracle, increasingly Veeva), Category 2 mid-tier systems, Category 3 modern specialist systems (Medrio, Viedoc, Replior, DSG and similar), Category 4 core-plus-custom systems, and Category 5 open source (OpenClinica, REDCap). For a detailed comparison of leading platforms, see our guide to top EDC vendors. Your macro criteria profile typically points to one or two candidate categories before you evaluate any specific product.
Step 5. Shortlist candidates and run a 360-degree verification. Within candidate categories, identify 2–3 specific systems and providers. Issue RFIs focused on your macro criteria rather than a generic functional checklist. Conduct demonstrations on scenarios that reflect your pipeline, not a vendor's canned demo. Verify each dimension: functional range, service capacity, provider stability, and total cost and conditions.
Step 6. Select, verify against red lights, and contract. Choose the best-matching option and confirm it meets your minimum requirements across all four dimensions. Take red lights seriously — a financially unstable provider, a service capacity gap, or a compliance shortfall are not minor issues to accept for convenience. If the best available option is not good enough, return to Step 3. Otherwise, negotiate enterprise contract terms: pricing, flexibility, change control, and data portability.
Step 7. Plan implementation. A company-level selection is not complete at contract signature. Plan for standards library development, validation, internal training, and CRO onboarding. Early investment here compounds across every subsequent trial.
Common Company-Level Selection Mistakes
Selecting for current trials, not the pipeline. The platform that is perfect for your two Phase I trials may not scale to the Phase III programme you will start next year. Company-level selection must consider your plausible trajectory, not just current work.
Copying what bigger companies use. Established solutions at large pharma are the product of 10–20 years of investment in infrastructure, standards, and internal capability. A system that works for them in that context will not necessarily work for you in yours. What matters is fit to your situation — same components in a different setting produce a different result.
Selecting before the pipeline is clear. Ownership delivers benefits when there is a pipeline to amortise the investment across. Locking in too early — when direction, volume, and sourcing model are still fluid — risks a costly mid-course correction.
Delaying past the tipping point. Equally, waiting past the 2–3 parallel trial mark means missing cross-trial consistency and enterprise pricing on trials already underway. The window for clean implementation narrows with every trial you run on a CRO system.
Ignoring exit strategy. No platform is forever. Negotiate clear terms for data and metadata extraction, library portability, and contract exit at the outset. The time to plan for the possibility of switching is before you are locked in.
Treating the decision as a CDM-only exercise. Company-level EDC selection touches sourcing strategy, contracting, IT, clinical operations, and regulatory affairs. A decision made in isolation by data management frequently misses material considerations from these functions.
Underestimating implementation effort. Selecting the system is perhaps 30% of the work. Standards library development, validation, training, and CRO onboarding are the other 70% — and they determine whether the selected system actually delivers its benefits.
Company-Level EDC Selection and TriTiCon Training
A well-made company-level EDC selection depends on understanding how the choice will cascade through every subsequent trial — standards, sourcing, validation, close-out, and submission. TriTiCon's clinical data management training covers this full lifecycle, including the macro criteria approach to strategic system decisions. The training enables data management leaders to engage with company-level EDC decisions as strategic exercises rather than technical feature comparisons.
Explore the TriTiCon course platform and free resources.
Frequently Asked Questions
When is the right time for a company-level EDC selection?
The benefits of ownership typically begin to outweigh the burden at 2–3 parallel trials. For therapeutic areas with complex trial designs — oncology or rare disease, for example — the tipping point can come earlier, sometimes from trial one. For simple early-phase programmes with no defined follow-on pipeline, trial-by-trial sourcing remains appropriate until the pipeline develops.
Should we standardise on one platform, or maintain flexibility?
Most companies benefit from a single primary platform supplemented by pragmatic exceptions. Cross-trial consistency, library re-use, and enterprise pricing all depend on concentration. A genuinely different trial — a first-in-human adaptive design, say, or a specialised imaging-heavy study — may justify a different system, but routinely spreading trials across multiple platforms undermines the case for ownership.
How long does a company-level selection take?
A structured macro criteria-driven selection typically takes three to four months from strategy definition through contract signature, with implementation adding another three to six months before the first trial goes live on the platform. Selections rushed to meet an immediate trial start often result in avoidable rework.
Can we change platforms later?
Yes. Trials are temporary and data is portable if you have maintained CDISC compliance and negotiated clear exit terms. Switching between trials is a process-and-cost exercise rather than a technical barrier. Switching an in-flight trial is possible but significantly harder and best avoided.
What happens to trials already running on CRO systems?
Existing trials can typically run to close-out on their current platform while new trials start on the selected company system. Migrating ongoing trials is rarely worth the effort. A transition plan should cover which trials stay, which migrate, and when.
How does this affect our CRO relationships?
Company system ownership changes the CRO relationship from "your system on your processes" to "our system configured to our processes, delivered through your services." This is a positive change for consistency and control, but requires deliberate CRO onboarding — technical training, process alignment, and standards familiarisation. CROs that resist working on client systems become less suitable partners.
What about 21 CFR Part 11 and regulatory compliance?
Sponsor responsibility for compliance does not change whether you own or source. At company level, you benefit from doing the qualification work once and reusing it across trials — a meaningful reduction in per-trial overhead compared with qualifying a different CRO system for every study. Recent regulatory focus has shifted towards hosting security, back-up processes, and system development processes, all of which should be part of your qualification review. For a detailed walkthrough of EDC validation requirements, see our practical guide to computer system validation.
Last Updated: May 2026
This article reflects general industry principles. Specific regulatory requirements should be verified against current FDA, EMA, and ICH guidance documents.
Related articles:
- Complete Guide to EDC Systems in Clinical Trials 2026
- EDC vs Paper CRFs: A Complete Comparison for Clinical Trials
- Top EDC Vendors 2026: Choosing the Right Platform
- EDC System Selection Guide: Trial-by-Trial Approach
- EDC Validation Requirements: Meeting FDA 21 CFR Part 11
- EDC User Training Best Practices for Clinical Trial Sites
